The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax wit ...

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...